Lactobacillus helveticus R0052 and No Significant Change in Endocannabinoid or Inflammatory Biomarkers

• Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 Supplementation: An Exploratory, Randomized, Placebo-Controlled Trial of Endocannabinoid and Inflammatory Responses in Female Dancers.

  • 2025-05-30
  • Clinical Trial
  • Microorganisms 13(6)
  • • Jakub Wiącek
    • Karolina Skonieczna-Żydecka
    • Igor Łoniewski
    • Chariklia K Deli
    • Ioannis G Fatouros
    • Athanasios Z Jamurtas
    • Dominika Moszczyńska
    • Joanna Karolkiewicz

  • PubMed: 40572172
  • DOI: 10.3390/microorganisms13061284

  1 Insight on

  • No Significant Change in Endocannabinoid or Inflammatory Biomarkers

  • Moderate evidence

  After 12 weeks, no statistically significant differences in the AEA, LPS, cytokine levels, or stress-coping strategies were observed between the probiotic and placebo groups (LPS-probiotic: +3.48 EU/L, p = 0.9361; placebo: +56.98 EU/L, p = 0.0694; AEA-probiotic: -1.11 ng/mL, p = 0.9538; placebo: +14.08 ng/mL, p = 0.4749).

  Effect

  Neutral

  Effect size

  Small

  Significant

  No